Editorial: If STRIDE‐II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails

Abstract

LINKED CONTENTThis article is linked to Dignass et al papers. To view these articles, visit https://doi.org/10.1111/apt.17622 and https://doi.org/10.1111/apt.17656

Editorial: If STRIDE‐II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails—Authors' reply

“…We thank Drs. Kedia and Ahuja for their insightful comments and for highlighting additional shortcomings in the management of Crohn's disease (CD) and ulcerative colitis (UC) 1,2 . Despite new therapeutic options, we still cannot achieve the desired long‐term outcomes of steroid‐free remission, mucosal and transmural healing, prevention of invalidity and disability, unimpaired quality of life and avoidance of long‐term therapy‐related adverse events in all patients with IBD 3 .…”